Long COVID is a condition where debilitating symptoms can persist for months after aCOVID-19 infection. This study aims to evaluate the effects of NE3107 on severalneurological symptoms reported in people with Long COVID including difficultyconcentrating or remembering things ("brain fog") and fatigue.Researchers will compare NE3107 to a placebo (a look-alike substance that contains nodrug) to see if NE3107 works to treat neurocognitive and fatigue symptoms of long COVID.Participants will: - Take NE3107 or a placebo twice daily for 84 days - Visit the clinic 5 times for checkups and tests and have a follow up phone call
Not Provided
Drug: NE3107
20 mg Capsule
Other Name: bezisterim
Drug: Placebo
placebo capsule
Inclusion Criteria:
- 18 years to 64 years of age
- diagnosed with Long COVID with symptoms of fatigue and brain fog for at least 3
months
- agree to use birth control measures
- provide voluntary consent
- willing to allow blood collection
- pass all screening tests and procedures
Exclusion Criteria:
- has received a COVID-19 vaccination within 30 days
- previous admission to the intensive care unit for COVID-19
- medical history of major mental or physical illness prior to COVID-19 infection
Clinical Trial Site
San Francisco 5391959, California 5332921, United States
University of Colorado
Aurora 5412347, Colorado 5417618, United States
Clinical Trial Site
Jacksonville 4160021, Florida 4155751, United States
Centricity Research
Columbus 4188985, Georgia 4197000, United States
Clinical Trial Site
Silver Spring 4369596, Maryland 4361885, United States
Clinical Trial Site
Farmington Hills 4992523, Michigan 5001836, United States
University Hospitals Cleveland Medical Center
Cleveland 5150529, Ohio 5165418, United States
Zenos Clinical Research
Dallas 4684888, Texas 4736286, United States
West Virginia University
Morgantown 4815352, West Virginia 4826850, United States
Penelope Markham, PhD
pmarkham@bioviepharma.com
Not Provided